In the U.S., May is observed as Mental Health Awareness Month, a tradition that goes back to 1949. About 60 million American adults live with some form of mental illness, ranging from mild anxiety and depression to more severe psychiatric conditions, according to reports.
The theme for this year is "More Good Days, Together," focusing on community support.
Shifting focus to the regulatory landscape, the May FDA calendar appears relatively light.
The upcoming regulatory milestones include a potential label expansion of argenx SE's VYVGART, and an additional indication for Daiichi Sankyo Company and AstraZeneca plc's cancer therapy Enhertu. Also awaiting FDA decisions in May are Eisai's supplemental Biologics License Application for Leqembi iqlik, and a supplemental application from MannKind evaluating Afrezza use in pediatrics.
Let's take a look at the biotech stocks facing the FDA decisions in May 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.